Journal
JOURNAL OF DERMATOLOGICAL SCIENCE
Volume 64, Issue 2, Pages 85-91Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jdermsci.2011.07.008
Keywords
Galectins; Lectins; Skin inflammation; Skin cancer
Categories
Funding
- NIAID NIH HHS [R01 AI039620-08, R01 AI020958, R01 AI039620, R01 AI020958-24] Funding Source: Medline
- NIAMS NIH HHS [R01 AR056343, R01 AR056343-03] Funding Source: Medline
Ask authors/readers for more resources
Galectin-3 is highly expressed in epithelial cells including keratinocytes and is involved in the pathogenesis of inflammatory skin diseases by affecting the functions of immune cells. For example, galectin-3 can contribute to atopic dermatitis (AD) by promoting polarization toward a Th2 immune response by regulating dendritic cell (DC) and T cell functions. In addition, galectin-3 may be involved in the development of contact hypersensitivity by regulating the migratory capacity of antigen presenting cells. Galectin-3 may act as a regulator of epithelial tumor progression and development through various signaling pathways, such as inhibiting keratinocyte apoptosis through regulation of the activation status of extracellular signal-regulated kinase (ERK) and activated protein kinase B (AKT). Galectin-3 is detected at different stages of melanoma development. In contrast, a marked decrease in the expression of galectin-3 is observed in non-melanoma skin cancers, such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Galectin-3 may play an important role in tumor cell growth, apoptosis, cell motility, invasion, and metastasis. Galectin-3 may be a novel therapeutic target for a variety of skin diseases. (C) 2011 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available